Changes in serum potassium in people with type 2 diabetes taking sodium-glucose co-transporter-2 inhibitors.
使用鈉-葡萄糖共轉運蛋白-2抑制劑的2型糖尿病患者血清鉀變化。
Pharmacotherapy 2025-02-24
Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus.
在晚期慢性腎病和第二型糖尿病患者中,鈉-葡萄糖共轉運蛋白 2 抑制劑對鈣磷穩態的影響。
Diabetes Res Clin Pract 2024-08-11
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors.
SGLT-2 或 DPP-4 抑制劑啟動後高鉀血症與維持腎素-血管緊張素系統抑制劑治療的關聯。
Nephrol Dial Transplant 2024-10-09
Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium-glucose cotransporter-2 inhibitor therapy: A multicentre database analysis in Taiwan.
初始血清鈉變化與接受鈉-葡萄糖共轉運蛋白-2抑制劑治療的糖尿病患者臨床結果的關聯:台灣多中心數據庫分析。
Diabetes Obes Metab 2024-10-21
Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis.
糖尿病腎病患者中 RAASi 和 SGLT-2i 治療引起高鉀血症的發生率:系統性回顧與網絡Meta分析。
Front Pharmacol 2025-02-11
Long-term effect of sodium-glucose cotransporter 2 inhibitors in kidney functions: A systematic review and meta-analysis.
鈉-葡萄糖共轉運蛋白 2 抑制劑對腎功能的長期影響:系統性回顧與統合分析。
Medicine (Baltimore) 2025-02-17
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease.
鈉-葡萄糖共轉運蛋白 2 (SGLT2) 抑制劑與 2 型糖尿病患者及 1-3 期慢性腎病的慢性腎病-礦物質與骨骼疾病風險。
CMAJ 2025-02-24
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis.
鈉-葡萄糖共轉運蛋白-2 抑制劑對心臟衰竭患者血清鈉和鉀的影響:系統性回顧與荟萃分析。
BMC Cardiovasc Disord 2025-04-04